Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EASIVIRAL

Financiado

Cerrado

EASIVIRAL

In September 2016 WHO-Europe stated Europe is at a critical point with HIV. New diagnoses in the European Region recently increased by 76%. WHO urges an accelerated people-centered response based on taking HIV viral-load (VL) tes... ver más

30/11/2021

ALTRATECH LIMITED

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

ALTRATECH LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-11-30

SMEInst-05-2016-2017: Supporting innovative SMEs in the h...

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

ALTRATECH LIMITED

2.97M€ | Lider

Proyectos interesantes

HIVBIOCHIP

Medical Technol...

Data Science

2M€ Cerrado

CAPHIV

Medical Technol...

Data Science

1M€ Cerrado

POC-HCV

Medical Technol...

Data Science

8M€ Cerrado

RAPP-ID

Medical Technol...

Data Science

16M€ Cerrado

DECIPHER

Medical Technol...

Software

7M€ Cerrado

DISEÑO Y DESARROLLO DE MULTITEST PARA DETECCI...

Medical Technol...

Biotechnology

1M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 48 meses Fecha Inicio: 2017-11-25
Fecha Fin: 2021-11-30

Líder del proyecto

ALTRATECH LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto In September 2016 WHO-Europe stated Europe is at a critical point with HIV. New diagnoses in the European Region recently increased by 76%. WHO urges an accelerated people-centered response based on taking HIV viral-load (VL) testing out of labs and into local clinics where it is most needed at point-of-care (PoC). No such solution exists today. New disruptive innovations are needed to address this. AltraTech Ltd has developed three proven biotechnologies to capture, purify, and detect the HIV virus from a blood sample, in 40 mins, using proven HIV biomarkers. This enables life-saving clinical intervention, immediate prescription and therapy for the patient, and stops further spread of the virus. The three techniques are innovative. Their combination, in a portable battery-operated kit format, is disruptive. It offers the unique combination of portability, robustness, reduced cost, with simultaneous increase in accuracy, combo-detection of Hepatitis and other viruses, and elimination of refrigerated reagents. It will address the above crisis, the HIV-VL PoC market, and has the potential to disrupt the €1B viral clinical diagnostics market and displace RT-PCR diagnostics that have been used in laboratories for two decades. Following a successful SME-Phase-1 feasibility, the technology received a Seal-of-Excellence in Phase-2(PHC-12-2015) – exceeded funding threshold. TRL improvements have been made in 2016, and a new CEO, management structure, and new venture funding significantly enhances AltraTech capacity to commercialise EASIVIRAL and see it reach market acceptance. The outcomes will enable capture a market leading share of > 30% of the €210M PoC HIV-VL market, reach cumulative EBITDA for this product alone of more than €18M by 2024. AltraTech will create 75 new jobs during this time, grow its portfolio of granted patents on its disruptive EASIVIRAL technology, and increase the revenues, jobs, and competitiveness of its manufacturing supply partners

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores